12:25 PM EST - Gemina Laboratories : Announces that human subject testing for its COVID-19 rapid antigen test is in its final stages, with completion and full data readout expected in May 2022. With extremely encouraging results in hand from its Phase 1 work with International Point of Care, Gemina Labs moved into Phase 2 development work on its COVID-19 platform with human subjects. Gemina Laboratories
shares C.GLAB are trading down one cent at $0.54.
